Roche‘s Phase III ALLEGORY study showed that Gazyva®/Gazyvaro® (obinutuzumab) was effective in treating adults with systemic lupus erythematosus (SLE) who were receiving standard therapy. The results were groundbreaking, statistically significant, and clinically meaningful. The primary endpoint of the study was successfully met, demonstrating that, in comparison to standard therapy, a significantly higher percentage of patients receiving Gazyva/Gazyvaro at one year (52 weeks) experienced a minimum four-point improvement in the SLE Responder Index 4 (SRI-4). All key secondary endpoints were also met, and no new safety signals were identified, aligning with the well-established safety profile of Gazyva/Gazyvaro.
According to Roche’s Phase III ALLEGORY study, adults with systemic lupus erythematosus (SLE) undergoing standard therapy responded well to Gazyva®/Gazyvaro® (obinutuzumab). The findings were clinically significant, statistically significant, and revolutionary. The study’s primary endpoint was successfully achieved, showing that a significantly higher percentage of patients receiving Gazyva/Gazyvaro at one year (52 weeks) had at least a four-point improvement in the SLE Responder Index 4 (SRI-4) compared to standard therapy. In keeping with Gazyva/Gazyvaro’s well-established safety profile, all important secondary endpoints were also satisfied, and no new safety signals were found.
Read More: Roche’s Gazyva/Gazyvaro Gets U.S. FDA Approval for Lupus Nephritis Treatment
Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are unprecedented in demonstrating that by effectively controlling disease activity, Gazyva/Gazyvaro may delay or prevent further organ damage in people with SLE.
We look forward to sharing the data with global health authorities, with the goal of making this potentially transformative new standard of care available as quickly as possible.
Levi Garraway
Over three million people worldwide suffer from SLE, with women of colour being disproportionately affected. Women are diagnosed with the condition most often between the ages of 15 and 45. Frequent flare-ups that cause inflammation and harm to several organs are a hallmark of the illness. Within five years of being diagnosed with SLE, about half of all patients will develop lupus nephritis, a potentially fatal kidney complication. Gazyva/Gazyvaro’s ability to improve disease control is essential for minimising flare-ups, preventing additional organ damage, and lowering the chance of developing lupus nephritis.
Read More: Roche’s Giredestrant Combination Shows Significant Benefit in Advanced ER-Positive Breast Cancer
Building on the success of the REGENCY study in lupus nephritis and INShore in idiopathic nephrotic syndrome, ALLEGORY is the third successful Phase III study for Gazyva/Gazyvaro in immune-mediated diseases. The potential of Gazyva/Gazyvaro to address disease activity across a range of autoimmune or immune-related diseases is highlighted by this expanding body of evidence. Gazyva/Gazyvaro provides a promising therapeutic approach by targeting and killing specific B cells, both directly and in tandem with the body’s immune system.
Roche’s goal to become a leader in immune-mediated rheumatology and nephrology diseases is further supported by its ongoing research into Gazyva/Gazyvaro in adults with membranous nephropathy and in children and adolescents with lupus nephritis.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
